



The

IMPROVE-CKD

AKTN 10.01

Results^{trial}

Thank you for taking part

The trial looked at whether a phosphate-lowering medication called lanthanum carbonate could reduce the risk of heart disease in people with chronic kidney disease.

Participants received either lanthanum carbonate or a placebo for up to 2 years.



278 adults with chronic kidney disease took part



18 hospitals in Australia, New Zealand & Malaysia were involved



2,722 Pulse Wave Velocities were completed



476 CT scans were performed



The results of this trial tell us that treatment with lanthanum carbonate over 96 weeks in this study population had no beneficial effect on arterial stiffness or aortic vascular calcification when compared to placebo.

The risk of heart disease in one group of participants was not different compared to the other group.



We are now not convinced that phosphate binders improve the risk of heart disease in people with chronic kidney disease and normal blood phosphate levels.

You helped researchers learn more about kidney disease.



Australasian Kidney Trials Network
www.aktn.org.au



If you have questions you can contact your study doctor